Cardiff Oncology (NASDAQ:CRDF – Get Free Report) and Protara Therapeutics (NASDAQ:TARA – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.
Volatility & Risk
Cardiff Oncology has a beta of 1.76, suggesting that its share price is 76% more volatile than the S&P 500. Comparatively, Protara Therapeutics has a beta of 1.56, suggesting that its share price is 56% more volatile than the S&P 500.
Insider and Institutional Ownership
16.3% of Cardiff Oncology shares are held by institutional investors. Comparatively, 38.1% of Protara Therapeutics shares are held by institutional investors. 7.8% of Cardiff Oncology shares are held by insiders. Comparatively, 12.5% of Protara Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cardiff Oncology | $490,000.00 | 356.87 | -$41.44 million | ($0.94) | -3.64 |
| Protara Therapeutics | N/A | N/A | -$40.42 million | ($2.82) | -1.60 |
Protara Therapeutics has lower revenue, but higher earnings than Cardiff Oncology. Cardiff Oncology is trading at a lower price-to-earnings ratio than Protara Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of current ratings and recommmendations for Cardiff Oncology and Protara Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cardiff Oncology | 0 | 0 | 3 | 0 | 3.00 |
| Protara Therapeutics | 0 | 0 | 3 | 0 | 3.00 |
Cardiff Oncology currently has a consensus target price of $10.33, suggesting a potential upside of 202.14%. Protara Therapeutics has a consensus target price of $22.67, suggesting a potential upside of 401.47%. Given Protara Therapeutics’ higher possible upside, analysts clearly believe Protara Therapeutics is more favorable than Cardiff Oncology.
Profitability
This table compares Cardiff Oncology and Protara Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cardiff Oncology | -6,238.17% | -73.97% | -60.40% |
| Protara Therapeutics | N/A | -55.96% | -49.06% |
Summary
Protara Therapeutics beats Cardiff Oncology on 8 of the 11 factors compared between the two stocks.
About Cardiff Oncology
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
About Protara Therapeutics
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.
Receive News & Ratings for Cardiff Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiff Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
